Fresh out of stealth, Switchpoint Bio raises €4.75 million to decode disease and drug response through blood tests
Switchpoint Bio, a TechBio startup based in Helsinki and Cambridge, Massachusetts, has raised €4.75 million ($5.3 million) in pre-Seed funding. The round includes a €4.48 million ($5 million) investment from Treehouse Delmar Investments. The company emerged from stealth earlier this year and is building a blood-based epigenomic platform meant to give drug developers a scalable view of how disease and treatment change human biology.
The company was founded in 2025 by Samuel Myllykangas, who is CEO, and Jason Buenrostro, who have worked together since developing targeted sequencing technologies at Stanford. Buenrostro is a MacArthur Fellow, a Harvard professor, Director of the Epigenomics Program at the Broad Institute, and inventor of the ATAC-seq profiling technology. Myllykangas previously built Blueprint Genetics, which Quest Diagnostics acquired in 2020. Three further co-founders are Niilo Färkkilä (Chief Commercial Officer), Jussi Paananen (Chief Technology Officer) and Mitja Kurki (Scientific Advisor).
The premise is that circulating immune cells carry epigenomic marks of disease, exposures and treatment. Switchpoint says this gives drug developers an immediate use in treatment response: showing what biology is present before treatment, what changes after a drug is given and by how much, and what persists despite treatment. The company argues that tracking these changes over time could give an earlier, more direct view of mechanism, response and resistance, and help show which patients benefit and why. It combines epigenomic profiling with AI, using a targeted DNA methylation assay on blood that focuses on regions relevant to disease and immune biology. The company says this gives deep, cost-efficient coverage of the most relevant parts of the methylome.
Switchpoint is now moving from platform development into clinical and industry validation. It is testing the approach in autoimmune disease, including systemic lupus erythematosus, to see whether disease-relevant immune states can be identified from blood and followed through treatment. The new funds will go toward that validation, larger clinical and biobank datasets, further development of the epigenomic and AI platform, and growing the team in Helsinki and Cambridge.